Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02527798 · ClinicalTrials.gov registry record · Phase 2
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)
A Phase 2 study of Bronchopulmonary Dysplasia, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 20
- Study locations
NCT02527798: Completed Phase 2 study of Bronchopulmonary Dysplasia, sponsored by University of North Carolina, Chapel Hill.
NCT02527798 is a Phase 2 study of Bronchopulmonary Dysplasia that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 82 participants, below the 233-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02527798, a Phase 2 study of Bronchopulmonary Dysplasia, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will describe the safety of furosemide in premature infants at risk of bronchopulmonary dysplasia and determine the preliminary effectiveness and pharmacokinetics (PK) of furosemide. Funding Source - FDA OOPD
Primary Outcome
Safety was assessed following the initial study-specific procedure (e.g., screening blood draws, dosing) through 7 days post last study dose by frequency and incidence of adverse events and serious adverse events.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Furosemide Cohort 1
- DRUG Furosemide Cohort 2
- DRUG Furosemide Cohort 3
Study Locations (20)
Florida
- University of Florida Jacskonville Shands Medical Center - Jacksonville
- Wolfson Children's Hospital - Jacksonville
- South Miami Hospital - South Miami
- John's Hopkins Al Children's Hospital - St. Petersburg
Massachusetts
- Floating Hospital for Children at Tufts Medical Center - Boston
- UMass Memorial Medical Center - Worcester
North Carolina
- The University of North Carolina at Chapel Hill/North Carolina Children's Hospital - Chapel Hill
- New Hanover Regional Medical Center - Wilmington
Ohio
- MetroHealth Medical Center - Cleveland
- Nationwide Children's Hospital/The Ohio State University - Columbus
Arkansas
- Arkansas Children's Hospital/University of Arkansas for Medical Sciences - Little Rock
California
- Loma Linda University Medical Center - Loma Linda
Illinois
- University of Illinois at Chicago - Chicago
Kansas
- Wesley Medical Center - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2015-11-27 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 2 |
What the finished NCT02527798 record still lists
NCT02527798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 233-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Bronchopulmonary Dysplasia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02527798 names 20 study sites across 14 states, led by Florida, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02527798 about?
NCT02527798 is a clinical study titled "Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)". This study will describe the safety of furosemide in premature infants at risk of bronchopulmonary dysplasia and determine the preliminary effectiveness and pharmacokinetics (PK) of furosemide. Funding Source - FDA OOPD
What is the current status of trial NCT02527798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2015-11-27. Estimated completion is 2019-10-15.
What conditions does trial NCT02527798 study?
This clinical trial studies the following conditions: Bronchopulmonary Dysplasia.
What interventions are being tested in trial NCT02527798?
The interventions under investigation include: Placebo (OTHER), Furosemide Cohort 1 (DRUG), Furosemide Cohort 2 (DRUG), Furosemide Cohort 3 (DRUG).
Who is sponsoring clinical trial NCT02527798?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02527798 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchopulmonary Dysplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02527798's enrollment target sits among peer trials
82 22nd of 29 higher than 8 of 29 other Bronchopulmonary Dysplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bronchopulmonary Dysplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
RECRUITING · Phase 2
-
Vitamin D Supplementation for Extremely Preterm Infants
COMPLETED · Phase 2
-
Safety of Sildenafil in Premature Infants
COMPLETED · Phase 2
-
Trial II of Lung Protection With Azithromycin in the Preterm Infant
COMPLETED · Phase 2
-
Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
COMPLETED · Phase 2
-
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI